Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Francine M Foss; Youn H Kim; H Miles Miles Prince; Timothy M Kuzel; Costas K Yannakou; Chean Eng Ooi; Dongyuan Xing; Nicholas Sauter; Preeti Singh; Myron Czuczman; Madeleine Duvic

Journal article

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

Francine M Foss, Youn H Kim, H Miles Miles Prince, Timothy M Kuzel, Costas K Yannakou, Chean Eng Ooi, Dongyuan Xing, Nicholas Sauter, Preeti Singh, Myron Czuczman, Madeleine Duvic

BLOOD | ELSEVIER | Published : 2022

DOI: 10.1182/blood-2022-166916

Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302

University of Melbourne Researchers

Citation metrics

Keywords